Summary of PRA Health Sciences, Inc. (NASDAQ:PRAH) Ratings as of Jun 26, 2018

June 26, 2018 - By Lena Young

PRA Health Sciences, Inc. (NASDAQ:PRAH) Corporate Logo

PRA Health Sciences, Inc. (NASDAQ:PRAH) Ratings Coverage

In total 6 analysts cover PRA Health Sciences (NASDAQ:PRAH). “Buy” rating has 5, “Sell” are 0, while 1 are “Hold”. (NASDAQ:PRAH) has 83% bullish analysts. 7 are the (NASDAQ:PRAH)’s ratings reports on Jun 26, 2018 according to StockzIntelligence Inc. On Tuesday, January 30 the stock of PRA Health Sciences, Inc. (NASDAQ:PRAH) earned “Buy” rating by KeyBanc Capital Markets. On Thursday, February 22 the rating was maintained by Jefferies with “Buy”. On Wednesday, January 24 the stock of PRA Health Sciences, Inc. (NASDAQ:PRAH) has “Neutral” rating given by Mizuho. On Thursday, January 18 the firm has “Buy” rating by Robert W. Baird given. On Thursday, February 22 the stock of PRA Health Sciences, Inc. (NASDAQ:PRAH) earned “Outperform” rating by Credit Suisse. On Monday, January 22 the rating was maintained by SunTrust with “Buy”. On Monday, February 26 the firm has “Buy” rating given by SunTrust. Listed here are PRA Health Sciences, Inc. (NASDAQ:PRAH) PTs and latest ratings.

26/02/2018 Broker: SunTrust Rating: Buy New Target: $110.0 Maintain
22/02/2018 Broker: Jefferies Rating: Buy New Target: $103.0 Maintain
22/02/2018 Broker: Credit Suisse Old Rating: Outperform New Rating: Outperform Old Target: $101 New Target: $104 Maintain
30/01/2018 Broker: KeyBanc Capital Markets Rating: Buy New Target: $100.0 Maintain
24/01/2018 Broker: Mizuho Old Rating: Buy New Rating: Neutral Old Target: $82 Downgrade
22/01/2018 Broker: SunTrust Rating: Buy New Target: $105.0 Maintain
18/01/2018 Broker: Robert W. Baird Rating: Buy New Target: $98.0 Maintain

The stock decreased 1.67% or $1.57 during the last trading session, reaching $92.67.PRA Health Sciences, Inc. has volume of 55,716 shares. Since June 26, 2017 PRAH has risen 12.34% and is uptrending. PRAH underperformed the S&P500 by 0.23%.

PRA Health Sciences, Inc., a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide.The company has $5.94 billion market cap. The firm offers integrated services, such as data management, statistical analysis, clinical trial management, and regulatory and drug development consulting.The P/E ratio is 70.2. It also provides product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

Another two news for PRA Health Sciences, Inc. (NASDAQ:PRAH) were recently published by: 247Wallst.com on June 13, 2018 with title “4 Pharmaceutical Services Stocks To Buy With Big Upside Potential”. The other Bizjournals.com‘s article was titled “Contract research giant plans new Lenexa lab” and published on June 04, 2018.

PRA Health Sciences, Inc. (NASDAQ:PRAH) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.